In this episode, Alexa interviews Dom Farnan: Founder of DotConnect; author of the best seller, “Now Here: A Journey from Toxic Boss to Conscious Connector”; and Founder and Chief Consciousness Connector of DoseConnect™, a first-of-its-kind company blending organizational strategy, systems thinking, and talent acquisition in the psychedelic space.
Farnan shares her personal journey with psychedelics, discussing her experiences with psilocybin, ayahuasca, and 5-MeO-DMT, and how the last few years of her life have been focused on slowing down and integrating those experiences. She discusses the current state of the psychedelic industry, including downsizing and company closures, but also opportunities from networking, community engagement, and volunteering. She believes that while options may not be clear now, they will be there in the future, and may be jobs we never anticipated. So get to know companies now, and pay close attention with good discernment – not everything is as it appears.
She discusses her experiences with mentors and coaches; how psychedelic journeys and integration build onto each other; the importance of journaling; the need for patience as the industry grows; her book and the concept of conscious leadership over toxic leadership; and the beauty of embracing the openness we experience after a psychedelic experience: Can we use what we’ve learned to reprogram what we’re taught about life, invest in ourselves, let go of dissenting and limiting voices, and truly redefine what success (and happiness) means to us?
Click here to head to the show notes page.
In this episode, Kyle interviews author of Recapture the Rapture: Rethinking God, Sex and Death In a World That’s Lost Its Mind; speaker; and Founder of the Flow Genome Project, which researches and trains on improved human performance.
This episode – the last of the many recorded at Psychedelic Science 2023 – may ruffle some feathers, as Wheal is very outspoken and opinionated, focusing on what he spoke about at the conference: the pitfalls of the psychedelic movement. While his outlook is negative, he speaks with humor, and these shadow aspects are issues we need to be talking about: how the nature of capitalism and returning profits to shareholders affects the concept of set and setting; how easy it is to prescribe ketamine and the puppy mill clinics popping up everywhere; how innovators are racing to the bottom to get ahead; the designer drug epidemic likely leading us to a Prozac Nation 2.0; digital narcissism, Instagram “Shamans,” and the dangers of cults; chemists trying to take the experience out of the drug; the overuse of psychedelics creating super egos; and much more.
While he believes the hype and excitement of the psychedelic renaissance is leading us towards a trough of dissolution and that people aren’t turning their amazing experiences into net positives anywhere near enough, he believes that fewer people using psychedelics less often and more intensely – with initiatory practices, intentions, integration, and honest self-reflection – will help us all climb out of our egos and move towards a healthier society. There is hope, but we need to honestly look at all the shadow aspects in order to move towards it.
In this episode, David interviews psychiatrist, main researcher behind the first US Phase II trial of MDMA-assisted psychotherapy, and Senior Medical Director at MAPS Public Benefit Corporation: Dr. Michael Mithoefer; and Research Group Lead at the University of Zurich, and Principal Clinical Biomarker Lead at Boehringer Ingelheim, Katrin Preller, Ph.D.
Mithoefer, Preller (and David) are speakers at the upcoming Psychedelic Medicine – Israel, which will now take place July 28 - 31, 2024, in Tel Aviv. They discuss the conference and their current research: Preller's neuroimaging and work with psilocybin for alcohol use disorder, and Mithoefer (likely) being extremely close to seeing the FDA approve MDMA-assisted psychotherapy. He talks about how the therapeutic protocols for MDMA-assisted psychotherapy were created, what it's like to be so close to legalization, and how the next challenges will be accessibility and not minimizing therapy in favor of faster turnover.
They discuss neuroplasticity and whether or not it actually translates into something in humans; the concept of performing brain scans before a psychedelic experience to look for trauma biomarkers (and how this could actually result in savings over time); the excitement of seeing clinical work and neuroscience progressing in parallel; why integration frameworks need to be individualized; and the importance of embracing different therapeutic approaches.
Click here to head to the show notes page.
In this episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D. once again take over hosting duties, this time interviewing Gül Dölen, MD, Ph.D.: Associate professor of Neuroscience and Neurology at the Johns Hopkins University, School of Medicine, and head of the Dölen lab.
Dölen largely researches the neuroscience behind social behaviors and is most known for her work in establishing how psychedelics reopen critical periods of learning, and that the true benefit of psychedelics could be in learning how best to reopen those critical periods, how long they’re open for, and which therapeutic frameworks and integration practices could best take advantage of them. Her most recent research was giving MDMA to otherwise very asocial (and violent) octopuses to prove that a drastically different species would exhibit typical MDMA-inspired prosocial behavior. And, after discovering that all the classic psychedelics worked to reopen critical periods – that psychedelics are apparently the master key to opening these periods – she’s now researching why, through the PHATHOM project (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability).
You will likely learn a ton in this episode: why critical periods close as we get older and what may impede them from opening more often; how plasticity and metaplasticity relate to each other and why increased neuroplasticity isn’t always a good thing; how the length of different psychedelic experiences relates to efficacy; why the different results of MAPS’ and Compass Pathways’ studies show the importance of therapy; how autism could be related to critical periods; why repeated psychedelic use may make it harder for one’s brain to reset; and how important context is in the ability to reopen critical periods – especially around social learning.
Click here to head to the show notes page.
In this episode, Joe interviews Federico Seragnoli: coordinator of the ALPS Foundation, psychologist who works with patients undergoing compassionate use treatments with psychedelics, and Founder of the ALPS Conference.
This year, the ALPS Conference (which stands for Awareness Lectures on Psychedelic Science) takes place Oct. 27 – 29 at the Bâtiment des Forces Motrices in Geneva – a prime location for a conference due to Switzerland’s legality around psychedelics, where any citizen can apply for psilocybin or LSD therapy if they fall into the category of ‘treatment-resistant.’ Seragnoli discusses how the conference was originally inspired by an article on the MAPS blog about how to be a psychedelic researcher; and talks about its humble beginnings, its new location, and why it’s moved across the country each year. The conference features names like Rick Doblin and Michael Mithoefer, but he’s most excited about the smaller size of the event and the panel discussions, which gives attendees a chance to ask questions and hear some real conversations.
He discusses the vibrant field of psychedelic therapy and research in Switzerland; the importance of compassionate use and the criteria physicians need to be able to use it; the impact of students creating psychedelic associations at their universities; and Seragnoli’s new research: seeing if there is a link between cognitive science and a conceptualization of science – if you can model consciousness off neuroscience, can you model it off how you feel?
Click here to head to the show notes page.
In this episode, Johanna interviews Jungian analyst-in-training, writer, researcher, 5Rhythms® teacher, and Vital graduate: Mackenzie Amara; and Vital instructor, clinical psychologist, and creator of our new course, “Illuminating the Hidden Self: Navigating the Jungian Shadow with Psychedelics“: Dr. Ido Cohen.
This sequel to their fascinating discussion about shadow work earlier this year focuses on dreams, as Amara, while dreaming that she was having an acid trip and coming to the realization that dreams and LSD may be sending her to the same place, is researching the similarities between the odd worlds of dreams and psychedelic experiences: Is it the same place? Do the dreams we have after psychedelic experiences continue those visions and ‘Aha!’ moments? Can they answer questions for us (the concept of “sleep on it”)? Does dream analysis result in a greater feeling of integration? Can we use the dreams we have before experiences to help guide the experience itself?
The conversation goes a lot of places: the many aspects of Jungian psychology; the fluidity of Indigenous perspectives around visible and invisible worlds; how Jung wrote “The Red Book”; the concept of eros and reclaiming our relationship with aliveness; how nature is in constant equilibrium (as are we); how to build a relationship with your dreams; how to work with symbols in dreams; and much more. Ultimately, this episode is about the clash between the conscious and unconscious, the willed and the incidental, and waking life and other realities, and dream analysis and integration work is really tracking vitality in the human psyche: what is alive in us and how does it want to live out in our beings? What makes us come alive? Can our dreams tell us?
In this episode, Joe interviews Louie Schwartzberg: renowned filmmaker known for the award-winning documentary, “Fantastic Fungi”; and now, director of the new film, “Gratitude Revealed.”
He talks about his path to photography and filmmaking and how psychedelics were a huge inspiration – how his techniques of slowing down, speeding up, and zooming in were ways to capture the invisible aspects of reality – that which is “too slow, too fast, too small, and too vast for the human eye,” but is always there. He discusses the premiere of “Fantastic Fungi” and the waves it spread through the psychedelic space; The Louie Channel, his new streaming channel that will feature all his work in 4k and the work of other curated artists and friends; and the clinical trial he’s involved in to see if participants have better results in the treatment of their alcohol use disorder by watching his imagery set to music on an 80-inch screen while on psilocybin – research that hopefully leads to the concept of being able to prescribe images and music to people based on specific criteria.
He discusses his new film, “Gratitude Revealed,” which explores the power of gratitude: making it a daily practice (and especially a post-psychedelic integration practice), how resilience is one of the best benefits from practicing gratitude, and how easy it is to stop a rumination spiral by simply finding something to be grateful for. He also talks about the blessing of being a photographer and always thinking of beauty; how psychedelics make people more environmentally conscious; tripping with parents; how a shared love of nature could be the bridge between opposing sides; and how the best way to deal with the climate crisis is to start in your own yard.
You can watch “Gratitude Revealed” now, and then, on October 25th, we’re hosting a Q+A with Louie Schwartzberg on our Navigators platform. head to psychedelicstoday.com/events for details.
Click here to head to the show notes page.
In this episode, Joe interviews Deborah C. Mash, Ph.D.: neuroscientist; Professor Emerita of Neurology and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine; and leading researcher in addiction and brain disorders for over 30 years.
She is also the CEO and Founder of DemeRx Inc., a clinical stage drug development company working to advance ibogaine and its active metabolite, noribogaine, for the treatment of opioid use disorder. She talks about the Federal and state complications behind ibogaine research, the need for partnerships between clinics and researchers, what needs to be done to collect much needed Phase II and III ibogaine data, and why this all has to be in partnership with the FDA.
And she discusses much more: her story of how studying Cocaethylene led to her finding out about ibogaine; ibogaine and QTc-prolongation; deaths related to iboga and the amount of variables that aren’t considered; how the French were essentially using noribogaine in the 1930s; and, as this was recorded at Psychedelic Science 2023, her thoughts on the event and Rick Doblin’s opening statement.
Click here to head to the show notes page.
In this episode, David interviews Madison Margolin: NY-based, psychedelics and Judaism-focused journalist; host of the Set & Setting podcast; co-founder of DoubleBlind Magazine and the Jewish Psychedelic Summit; and author of the soon-to-be released, Exile & Ecstasy: Growing Up With Ram Dass and Coming of Age in the Jewish Psychedelic Underground.
They explore the relationship between Judaism and psychedelics, with Margolin sharing her experiences growing up in a Hindu-Jewish family; her personal journey with her Jewish identity; and how her use of psychedelics has deepened her life. She talks about the significance of Jewish holidays, and how holiday traditions connect them to nature and themselves in a very psychedelic way; the importance of intentionality; the beauty in dancing through an uncomfortable ayahuasca experience; the Jewish Psychedelic Summit; whether or not ancestors were using substances (and does that matter?), and why being in Israel feels so different – and psychedelic.
Margolin is an instructor in our new course, “Navigating Psychedelics: Jewish Informed Perspectives,” where she will be leading discussions on setting sacred time and space, particularly focusing on the significance of Shabbat and the energetic frequencies that are at play during certain holidays. The 9-week course begins next week – October 10 – so sign up now!
Click here to head to the show notes page.
In this episode – with the 2024 edition of Vital announced and applications officially open – we’re launching another series of Vital Psychedelic Conversations, with David hosting Jasmine Virdi: Vital instructor, writer, educator, and activist who works at Synergetic Press and volunteers for Fireside Project; and Tabata Gerk: Vital student, psychotherapist, and facilitator.
As always, they discuss what they think the most vital conversation should be right now, largely expressing concerns over the medicalization of psychedelics and the idea of a ‘traumadelic culture,’ where psychedelics are often only seen as healers of trauma and not doorways to mysticism and new ideas. And they point out another concern: the romanization of Indigenous culture and not recognizing that these are contemporary cultures that are affected by the same Western, capitalist paradigms that affect us all.
They also discuss the concept of epistemic injustice and needing to respect other ways of knowing; hyper-individualism and why we became so reductionist as a society; the role of money (who defines the problem and the solution?); concerns over who decides who is allowed to use these substances; the power of small steps of change; and, through talking about Gerk’s recent Amazonian ayahuasca experience, they dig into what it is about these experiences and surrounding communities that make them so special. Could we take some of that and effectively incorporate it into our Western models?
Click here to head to the show notes page.
In this episode, Joe interviews Ethan Nadelmann: author, speaker, Founder and former Executive Director of Drug Policy Alliance, host of the PSYCHOACTIVE podcast, and one of the leading voices in drug policy reform and harm reduction.
Nadelmann shares his journey from Princeton University to founding Drug Policy Alliance, to working with George Soros, encouraging Gary Johnson to push cannabis legalization, and interacting with prominent figures like Milton Friedman and Grover Norquist. He explores the motivations behind the drug war, the massive growth of incarcerations it led to, why the US spread its war on drugs abroad even when it went against our best interests, and, thankfully, the progress made in fighting the drug war – particularly with cannabis and psychedelics.
And he discusses much more: the banning of drug testing kits; the damages of our slow learning curve against the idea of a safe supply; the risks of under-prescribing opioids for people who actually need them; how libertarians, the right, and left are all starting to become against the drug war for the same reasons; why cigarette smokers should all switch to vaping; the concept of needing to pass a test at the pharmacy to prove you understand (and won't abuse) medication; and some strong arguments for decriminalization as an incremental step. And he asks some pretty important questions that we can all simmer on for a bit: how do we find a balance between helping people and not opening the rest of society up to harm? How do we challenge abuse in a way that doesn't hurt future harm reduction efforts? And how do we incentivize people into acting in their own best interests?
Click here to head to the show notes page.
In this special episode, Melanie Pincus, Ph.D. and Manesh Girn, Ph.D., who joined David in episode 403 to discuss the launch of their new course, essentially interview each other.
As the 2nd edition of their popular course, Psychedelic Neuroscience Demystified, begins on November 1, we wanted to give them a chance to highlight some of the aspects of neuroscience students can expect to learn in the course, and what so many people who are interested in psychedelics don’t fully understand: What does neuroplasticity actually entail? Can one predict if a patient is more apt to have an experience with ego dissolution? How does the amygdala relate to mood disorders? When are critical periods of greater plasticity and socialization at their most beneficial? How does neuroplasticity relate to chronic stress?
They also discuss lessons they’ve received from their own journeys; why they created the course; serotonin; psychological flexibility; body-based versions of self vs. memory-based versions; psychedelics and re-encoding memories (and the potential for false memories); how psychedelic therapy is different from standard drug treatments; psychedelics and the default mode network (is the story oversimplified?), and much more.
Click here to head to the show notes page.
In this episode, Kyle interviews Rachel Harris, Ph.D.: Psychologist in private practice for over 40 years, researcher who has published more than 40 peer-reviewed studies, and author of the new book, Swimming in the Sacred: Wisdom from the Psychedelic Underground.
She talks about graduating college and going straight to Esalen, where she had little concern over therapy or integration, and how, after 20 years of ayahuasca experiences, she learned to see psychedelic-assisted therapy and ceremonial, transformational experiences as very different things. She discusses her ayahuasca journeys; a surprising MDMA experience; what having an ongoing relationship with the spirit of ayahuasca means; Ann Shulgin’s concerns over going through death’s door while in a journey; what true integration is; how psychedelics can help prepare for death, and more.
And she talks about her new book, Swimming in the Sacred, which collects the stories, unique perspectives, and wisdom of 15 female elders who have been working in the underground for at least 15 years each, and how their experience has led to a somatic-based intuition and ‘know it in their bones’ feeling that so many new practitioners and facilitators need – and can only come with time.
Click here to head to the show notes page.
Last year, Joe attended his first Burning Man, and sadly, we didn’t hear much about it. In this episode, recorded just a few days after Joe returned from his second outing of nearly 12 days on the playa, Victoria changes that, asking Joe all the burning questions we all want to know.
He talks about preparing for Burning Man and the numerous obstacles he and his partner, Ali, encountered on their very slow journey there; the media’s interpretation of the rain and mud vs. the reality of being there in the middle of it all; the bogus reports of an ebola outbreak and disaster zone surrounded by FEMA officials (and was that all a prank by Burners?); the debate over the environmental impact of such a massive event, and more.
And he talks about the many joys of Burning Man: how, despite the weather and needing to remain at camp more, the community, abundance, embracing of all that is weird, and passion to share and make the best of it all made this a better year for him in many ways. He learned the importance of patience, avoiding a frantic state, and fighting panic with positive vibes, which was made infinitely more easy with the Big Krab Car: the art car Ali built and they drove around, DJing on all week.
Click here to head to the show notes page.
In this episode, Kyle interviews General Stephen Xenakis, MD: an adult, child, and adolescent psychiatrist who retired from the U.S. Army in 1998 at the rank of Brigadier General and began a career starting up medical technology companies and clinical practice to support human rights and new methodologies of healthcare.
In June, he became the new Executive Director of the American Psychedelic Practitioners Association (APPA), whose mission is to bring practitioners together as a community; develop the best training programs and practices; shift to a more patient-centered, integrated model of care; eventually accredit practitioners to practice with legal substances; and overall, help to make these new modalities more mainstream.
He discusses their path to success, which began with their publishing of the first professional practice guidelines for psychedelic-assisted therapy practitioners, and will continue on with ethical guidelines and clinical practice guidelines in the future. And he talks about the idea of a safety net for people who have adverse effects from psychedelic journeys; what clinicians need to know about psychedelics; concerns over accessibility; and the importance of identifying the correct treatments for the correct patients, as each person’s path to healing will likely be drastically different.
Click here to head to the show notes page.
In this episode, David interviews Dr. JoQueta Handy, Ph.D., IMD: speaker, author, educator, Natural Integrative Health Practitioner, and CEO and Chief Visionary of Brilliant Learning, Handy Wellness Center, and Brilliant Blends.
She shares childhood memories of growing up on her Grandparents’ farm, where she developed a deep appreciation for nature, staring at the stars, and the beauty in stillness, and how coming back to that stillness has been key in her life and psychedelic journeys. The conversation then shifts to all that she’s learned through her work with children on the autism spectrum: the problems of putting people into boxes; how autism affects everyone; the different ways people learn; the connection between autism and the gut microbiome; and how she has learned more from some of these children than any book could teach her – culminating in a story of discovering that a very challenged child people were ready to give up on could actually read and comprehend everything he was hearing.
She discusses her favorite adaptogens; the art of stacking adaptogens and different modalities; her multi-day coaching sessions; Internal Family Systems; quantum biofeedback; the use of supplements in microdosing; and Brilliant Blends, which sells blends of supplements designed to provide benefits as close to what psilocybin can provide (but legally) – inspired by the unique needs of autistic individuals. PT listeners can receive 10% off all purchases with code: PT10.
Click here to head to the show notes page.
In the first-ever episode of Hyphae Leaks, Mary and Reggie sit down with Joe Moore and share their backgrounds, impetus for launching a psychedelic tell-all podcast, and what listeners can expect from the first season.
Want to dig in on some of the topics discussed today? Quick links:
Catch Season 1 of Hyphae Leaks streaming NOW wherever you get your podcasts. New episodes every third Wednesday until Dec. 20. Rate, review, and subscribe!
In this episode, David interviews the President of the Psychedelic Medicine Association, host of the Psychedelic Medicine Podcast, and Psychedelics Today advisory board member and Vital contributor: Lynn Marie Morski, MD, JD.
She shares her journey with psychedelics and how they enabled her to leave a toxic job and pursue her passion for advocacy with vitality, and how important it is to focus your energy where it's best used. She talks about where we find ourselves in the psychedelic space based on Psychedelic Science 2023, as well as her recent TV appearances and the responsibility of preaching to the non-choir. And she discusses the idea of perfectionism in today's age; the need for psychedelic people to be involved in non-psychedelic conferences; the complications behind requiring physicians to experience psychedelics; the concept of it being malpractice for a physician to not mention psychedelic options; and the Psychedelic Medicine Association's upcoming virtual conference: Sana Symposium 2023, which happens October 26-27.
Morski talks a lot about the importance of educating healthcare professionals about psychedelics, debunking myths, and the need for standards in training therapists and primary care providers. She highlights how there is still no nationally-recognized certification for even ketamine providers, so how can people make informed decisions on who to trust? The Psychedelic Medicine Association is taking steps to improve this paradigm, offering a new course called "Managing Medical Risk in Patients Seeking Psilocybin Therapy," which will work to help clinicians make risk assessments for patients seeking psilocybin therapy – something that is not really being done today.
Click here to head to the show notes page.
In this episode, Alexa interviews Chase Hudson: Founder of HempLucid, a premium CBD wellness brand.
Hudson discusses his journey from being a firefighter to becoming involved in the cannabis and hemp industry, the origins of HempLucid, the restrictions they faced, and their current genetics and flagship water soluble tincture. He talks about the benefits of CBD and cannabis used in conjunction with psychedelic therapy - especially ketamine-assisted therapy, which he gives to his employees as a benefit. And he talks about Lamar Odom and the documentary he executive produced, "Lamar Odom Reborn," which chronicles how Odom came back from rock bottom through high dose CBD, iboga, and ketamine therapy.
He also discusses the idea of cannabis as a gateway drug to healing; the need for insurance to cover psychedelic therapy; the changing landscape of Utah from religious ideology to psychedelics; ketamine as the bridge between old and new models of healthcare, and more. And they talk about their own journeys a lot, with Hudson telling the story of his powerful and life-changing ibogaine treatment, and Alexa sharing stories from her tragic car accident and recovery, as well as the ketamine sessions she recently began. The conversation ultimately becomes one about the need for education and conversation to help us all climb out from decades of drug war propaganda.
Click here to head to the show notes page.
In this episode, David interviews East Forest: Portland, OR-based producer, podcaster, ceremony guide, and musician, specializing in ambient, electronic, contemporary classical, and indie pop music largely to guide listeners through deep journeys.
Forest discusses his live performances and influences; how his music pairs with journeys and specific psychedelics; the difference in the connection and vibe from a live performance vs. a recording; the difference between single-artist music created specifically for sessions vs. Spotify playlists; the inhumanity of generative music; his Journey Space online music and journey platform; and the challenges of making money in a time when music is more prevalent than ever, but also more in-the-background and diluted.
He talks a lot about sound itself: the role of rhythm and sound in communication and personal transformation; how richer overtones and increased layers of sound increase effects; research into very low pulsating tones, and how more synthesized sound and the growth of AI has created a yearning for more authentic, imperfect sounds.
His newest album was just released August 18: “Music For The Deck of The Titanic,” an homage to the musicians who spent their last few hours playing songs for passengers amidst the chaos and tragedy – an album Forest sees as an offering to the chaotic moment we’re all in.
In this episode, Joe interviews Satya Thallam: Policy Advisor at the international law firm, Arnold & Porter; and longtime policy expert based in Washington, D.C. who previously served in senior roles at both the White House and the U.S. Senate.
Thallam was the lead author and negotiator of the Federal Right to Try Act, which grants terminally ill patients access to experimental therapies and substances that have completed Phase I testing but have not yet been approved by the FDA. He discusses its intricacies and benefits, how psychedelics were not a focus but were always obvious, whether or not it allows people to grow their own mushrooms, and more. He talks abut the implementation of the first Federal legalization of hemp under the Farm Bill in 2018, breaking down the history and detail of how it came to be, and why a difference of .3% in weight truly matters when establishing law.
He discusses the changing landscape of politicians and psychedelics; how local action creates a culture of inspiring Washington; the internal fight between different agencies and the endless lobbying it takes to get things done; how one needs to cater their argument by who is listening; risk assessment and judgment-proof operations; the concern over whether or not we got everything wrong with cannabis; and why we will likely begin seeing a lot of coalitions popping up in the psychedelic space.
Click here to head to the show notes page.
In this episode, Kyle interviews Lisa Wessing: Clinical Psychologist and facilitator specializing in harm reduction at Kiyumí retreats in The Netherlands.
Wessing shares her personal journey and the shift from being uninspired with studying psychology to being a part of space-holding in Mexico and finding her true path. She dives into the world of Kiyumí retreats, discussing their holistic healing approach using psilocybin, somatic movement, dance expression, and other methods supporting their four pillars of embodiment, nature, mindfulness, and art. She discusses their more long-term program with Dr. Gabor Maté integrating his Compassionate Inquiry framework; their Equity Program, which offers partial or full funding for people who may not have the financial resources or who come from marginalized communities (e.g. BIPOC & Queer); and the importance of integration as a continuous process and checking in with people much later to build their “Kiyumíty.”
Much of this discussion covers the challenges of somatic psychology and facilitation in group containers: how most people are somatically illiterate and the journey of becoming more somatic; what to do about someone laughing or singing in a group context; what moving into one’s body really means; and different ways of using art to integrate an experience.
As part of our Vital program, we are running a psilocybin retreat with Kiyumí from September 6-11, and we have some available spots left! If you like what you hear, you’ll be in The Netherlands in September, and want to have an amazing experience with us, click here for more info!
Click here to head to the show notes page.
In this episode, recorded in-person at Psychedelic Science 2023, Kyle interviews Senator for the Mexican Green Party, Alejandra Lagunes.
Lagunes is the first Senator in Mexico to promote the use of psychedelics, and has been organizing open parliaments to foster collaboration between researchers, scientists, politicians, and Indigenous people, culminating in a groundbreaking decriminalization initiative to decriminalize psilocybin and psilocin from list 1 to list 3 (meaning they could be prescribed), create a new chapter for entheogens (and move mushrooms there), build an economically beneficial framework for Indigenous people, protect ancestor knowledge by law, and make big bioconservation moves with changes to environmental laws.
She discusses her personal journey with depression, anxiety, and a life-saving ayahuasca journey; how Covid uncovered a crisis in meaning and an openness to talk about mental health; the need for accessibility and safety in psychedelics against challenges in politics and policy implementation; our mental health crisis and the need for innovation, education, and overcoming stigma; the influence of US drug control policies on international regulations; the power of storytelling; and why we need to go back to our origins.
Click here to head to the show notes page.
In this episode, Joe interviews Stéphane Lasme, a former professional basketball player from Gabon who is now a partner at SteddeCapital, a private markets investment platform investing long-term capital into U.S.- and Africa-based opportunities across sports ownership, infrastructure, technology and plant medicine.
Lasme speaks of his childhood, growing up in Gabon with more traditional Catholic values while journeying deep into the jungle to visit his Grandmother every summer. It was there that he embraced the cultural aspect of Gabon and community, and first learned of iboga, which he had a profound experience with at age 12, and would later revisit in his basketball days. He discusses the drive and passion that led him to become the first person from Gabon to play in the NBA, and the subsequent pressure, stress, cultural differences, and “ok, what now?” moments that came at the end. He talks about Gabonese traditions; how iboga improved his stress relief and mental focus; how embracing yoga and Buddhist methods of self-discovery improved his life; scientific reductionism vs. the magic of mystery and trying to define an experience; and more.
While Gabon allows for the export of iboga, Lasme’s goal is to build a lab and treatment center in Gabon and share the power of Gabonese culture with people – so they can experience the medicine in its own country, with its traditional rituals and music. He has begun the fundraising process, and through his investment and facilitation work, is working to get African athletes to invest back into Africa and make Gabon a major destination for iboga.
Click here to head to the show notes page.
In this episode, Kyle interviews The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins, and renowned researcher of nearly 20 years: Matthew W. Johnson, Ph.D.
Recorded in-person at MAPS’ Psychedelic Science after running an 8-hour workshop on psychedelic therapy for addiction treatment, Johnson was still happy to sit down with PT to explore a wide range of topics: the under-researched concept of integration; how to best take advantage of optimal neuroplastic windows; why psycholytic therapy used to be more common; how our current protocols and research models are largely arbitrary; and his hopes for new, experimental, and flexible models of psychedelic therapy.
He also discusses his ongoing smoking cessation studies; the Oregon model (are we doing therapy or not?); misrepresentation in psychedelic therapy and knowing your lane; and the role of music in psychedelics: why shouldn’t people pick the music they know will give them goosebumps?
Click here to head to the show notes page.